Share

    


In This Section

Home / Learn / Liver Cancer

Liver Cancer

Liver cancer, which includes hepatocellular carcinoma (HCC), is the second leading cause of cancer-related death globally, responsible for more than 600,000 deaths worldwide each year.

Although this cancer type is less common in the United States, the American Cancer Society estimates that for 2018, an estimated 42,220 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed and about 30,200 individuals will die of these cancers nationwide.   

In the U.S., rates of liver cancer in young adults have started to decline; however, the incidence of liver cancer has more than tripled over the past four decades. Nationally, death rates from liver cancer have increased by nearly three percent each year since 2000. 

Effective prevention and treatment strategies for liver cancer remain an area of need. Active research in liver cancer is underway, and in recent years several new therapies, including multikinase inhibitors and checkpoint inhibitor immunotherapy, are showing promise. Historically treatment options have fallen into two broad categories, resectable (operable) and unresectable (inoperable) disease. 

Source: American Cancer Society. Key Statistics About Liver Cancer.
Bucco D.  Promising Liver Cancer Treatments on the Horizon. Cure Today.

Multidisciplinary Hepatocellular Carcinoma Care

In partnership with the Cancer Support Community, the American Cancer Society, and the Global Liver Institute, ACCC is conducting the Multidisciplinary Hepatocellular Carcinoma Care education program with three primary goals:

  • To understand the current communication landscape between healthcare providers and patients with hepatocellular carcinoma (HCC).
  • To identify effective practices and potential gaps in provider-patient communication.
  • To provide peer-to-peer learning and resources for effective communication with and care coordination for patients with HCC.

As a first step, ACCC has conducted a survey to gain perspectives from patients, treating clinicians, and members of the multidisciplinary care team.
Learn More

  •  Making the Case for an HIV Oncology Clinic
    By Marco A. Ruiz, MD
    Though the incidence of AIDS-defining cancers (Kaposi’s sarcoma, non-Hodgkin lymphoma, and invasive cervical carcinoma) has decreased with the use of antiretroviral therapy, numerous studies suggest that non-AIDS-defining cancers (cancers not previously associated with HIV and AIDS) appear to be increasing in incidence.
  •  Highlights from ASCO 2018
    By Cary A. Presant, MD, FACP, FASCO
    ASCO 2018 offered a wealth of new data that will continue to transform clinical practice and cancer program development. Most important, implementation of the scientifi c advances we learned at ASCO 2018 will improve the length and quality of life of our cancer patients.